Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma.
Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma.
复制标题
DOI：
10.1158/2326-6066.cir-13-0213
复制
发表时间：
2014-08
影响因子：
10.1
通讯作者：
Borrello I
中科院分区：
文献类型：
--
作者：
Noonan KA;Ghosh N;Rudraraju L;Bui M;Borrello I
Myeloid-derived suppressor cells (MDSC) play a significant role in tumor-induced immune suppression. Targeting their function could improve antitumor therapies. Previously we demonstrated that phosphodiesterase 5 (PDE5) inhibition in MDSCs augmented antitumor immunity in murine models. Here we show how the addition of the PDE5 inhibitor, tadalafil, in a patient with end-stage relapsed/refractory multiple myeloma reduced MDSC function and generated a dramatic and durable anti-myeloma immune and clinical response. Strategies targeting MDSC function with PDE5 inhibitors represent a novel approach that can augment the efficacy of tumor-directed therapies.
